secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001558370-21-014445
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Q3 net loss $85.6M; UKONIQ revenue $2.0M; ublituximab BLA for RMS submitted
--------------------------------------------------------------------------------

- Net loss $85.6M Q3, $254.8M nine months; ex-stock comp net loss $71.6M and $207.8M.
- Product revenue $2.0M Q3, $4.3M YTD from UKONIQ launch (approx 7 months post-approval).
- BLA for ublituximab submitted for RMS; PDUFA date for U2 in CLL set for March 25, 2022.
- Cash $381.4M as of Sept 30; expected to fund operations into 2023.
- R&D $52.0M and SG&A $34.9M in Q3; costs increased due to regulatory submissions and launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000155837021014445/0001558370-21-014445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000155837021014445/tgtx-20211104x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-014445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer